发明名称 Composition comprising expression or activity regulators of AKAP12 for treating central nerve system diseases
摘要 The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical composition of the invention. The central nervous system diseases contemplated within the invention include post-traumatic stress syndrome, stroke, and spinal injury.
申请公布号 US9089554(B2) 申请公布日期 2015.07.28
申请号 US201214000587 申请日期 2012.02.21
申请人 SNU R&B Foundation 发明人 Kim Kyu-Won;Cha Jong-Ho
分类号 A01N37/18;A61K38/00;A61K39/395;C12N15/113 主分类号 A01N37/18
代理机构 Riverside Law LLP 代理人 Riverside Law LLP
主权项 1. A method of reducing inflammation-induced secondary injury in the central nervous system of a subject in need thereof by forming fibrotic-glial scars, the method comprising administering to the subject a composition comprising a pharmaceutically effective amount of TGF-β1 (transforming growth factor-beta 1) and retinoic acid as an activator of AKAP 12 (A-kinase anchoring protein 12) under oxygenated conditions to form fibrotic-glial scars, wherein the subject's level of inflammation-induced secondary injury is reduced following administration of TGF-β1 and retinoic acid compared to the subject's level of inflammation-induced secondary injury in the absence of TGF-β1 and retinoic acid.
地址 Seoul KR